Reduced-dose obinutuzumab induces remission in refractory ANCA-associated vasculitis: a report of 16 cases
Reduced-dose obinutuzumab demonstrates sustained remission in refractory or relapsing active AAV, achieving high long-term remission rates with an acceptable safety profile. No severe invasive infections were observed.
Authors
- Sheng Chen (ORCID: https://orcid.org/0000-0001-7428-7153)
- Wenyi Wu (ORCID: https://orcid.org/0000-0002-4958-8760)
- Juan Wang (ORCID: https://orcid.org/0000-0003-1309-9444)
Institutions
- Renji Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1624234
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00